Natco Pharma Limited has officially announced the launch of India's first semaglutide generic injection in multi-dose vial format, marking a significant milestone in the country's diabetes medication market. The company disclosed this development through a regulatory filing under Regulation 30 of SEBI listing requirements, positioning itself as the pioneer in providing this innovative delivery format for diabetes and weight management medication.

Product Launch and Regulatory Approval

Natco Pharma received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market generic semaglutide in India for both multi-dose vials and pen devices, based on clinical comparison studies. The launch coincides with Day 1 of patent expiry, demonstrating the company's strategic market entry timing.

Comprehensive Product Portfolio

The pharmaceutical company has introduced a complete range of semaglutide products with competitive pricing across multiple strengths and delivery formats.

Market Differentiation and Cost Advantages

Natco Pharma's strategic decision to launch semaglutide in vial format with customized syringes represents a significant innovation in drug delivery for this therapeutic category. The multi-dose vial format offers healthcare providers and patients an alternative to traditional pen delivery systems, potentially improving accessibility and reducing treatment costs substantially.

The pricing strategy demonstrates remarkable cost benefits, with the vial format being approximately 70% cheaper than pen devices and 90% cheaper than the innovator's brand. This positioning makes it the most affordable GLP-1 therapy currently available in the Indian market, significantly improving patient accessibility to this important therapeutic option.

Strategic Business Approach

Beyond direct sales, Natco Pharma is also offering the semaglutide product to third parties for co-marketing arrangements, expanding its market reach and distribution capabilities. The pen device launch is scheduled for April 2026, providing patients with multiple delivery options based on their preferences and healthcare provider recommendations.

This comprehensive product launch reinforces Natco Pharma's commitment to expanding its generic pharmaceutical portfolio while addressing critical healthcare needs in diabetes management, establishing the company as an innovator in accessible diabetes medication delivery systems.

Natco pharma Limited has received a disclosure from promoter group member Satya Vani Nannapaneni regarding the sale of equity shares in the open market. The transaction, completed on March 9, 2026, involved the sale of 45,000 equity shares of Rs. 2/- each, with the disclosure filed on March 11, 2026, in compliance with SEBI regulations.

Transaction Details

The share sale transaction presents the following key parameters:

Shareholding Changes

The transaction resulted in a reduction of Satya Vani Nannapaneni's stake in the company:

Regulatory Compliance

The disclosure was made in accordance with multiple SEBI regulations:

• Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
• Form C of SEBI (Prohibition of Insider Trading) Regulations, 2015
• Regulation 7(2) read with Regulation 6(2) for continual disclosure requirements

Satya Vani Nannapaneni is identified as a member of the promoter group and is based in Illinois, USA. The disclosure was submitted to both the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited.

Company Share Capital

Natco Pharma Limited's equity structure remains unchanged following this transaction:

The transaction represents a routine promoter group share sale conducted through established market mechanisms, with all regulatory disclosure requirements being met within the prescribed timeframes.